EvoLiver™ is the flagship blood test of our hepatology-led strategy, built on Mursla Bio's proprietary tissue-specific extracellular vesicles (TS-EV) platform.
The test is designed for liver cancer surveillance in patients with advanced liver scarring (cirrhosis including MASH F4), detecting cancer at an early stage, when curative intervention remains possible.
In April 2025, EvoLiver™ received FDA Breakthrough Device Designation, the first granted of any test in at least five years.
EvoLiver™ is the flagship blood test of our hepatology-led strategy, built on Mursla Bio's proprietary tissue-specific extracellular vesicle (TS-EV) platform.
The test is designed for liver cancer surveillance in patients with advanced liver scarring (cirrhosis, including MASH F4), detecting cancer at an early stage, when curative intervention remains possible.
In April 2025, EvoLiver™ received FDA Breakthrough Device Designation, the first granted to any test in the liver cancer surveillance space in at least five years.
Our initial focus is to transform the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths.
For example, 10 million people in the United States and Europe are at high risk of developing liver cancer each year, often due to a pre-existing medical condition such as cirrhosis. These patients are enrolled in surveillance programmes for early liver cancer detection, primarily through ultrasound imaging, which is recommended twice yearly due to the fast progression of liver cancer.
However, detection rates remain low because ultrasound lacks sufficient sensitivity, particularly in overweight individuals. Additionally, poor adherence to the programme is common, as it requires a separate appointment from routine blood tests and is hindered by the known limitations of ultrasound.
Cells release extracellular vesicles (EVs): tiny membrane-bound particles that carry proteins, RNAs, and other molecular cargo from active cellular processes. Every organ sheds its own population of EVs into the bloodstream.
These tissue-specific EVs (TS-EVs) provide a non-invasive window into the molecular state of internal organs.
In a peer-reviewed study in the Journal of Extracellular Vesicles, Mursla Bio showed that resolving EVs to their tissue of origin reveals disease biology that bulk EV analysis of the same blood misses: a new class of liquid biopsy, tissue-resolved at the point of capture.
For a visual explanation, watch our 3D video.
Mursla Bio's TS-EV platform isolates tissue-specific EVs directly from blood with NEXPLOR, its proprietary capture technology, and leverages their multiomic cargo, creating a new foundational data layer for precision medicine.
Machine learning enhances multiomic profiling across proteomics and RNA sequencing, enabling robust biomarker discovery from under 2 mL of plasma. Validated signatures are translated into scalable, cost-efficient clinical assays.
The platform supports longitudinal disease tracking and AI-powered patient stratification. It is organ-agnostic: the hepatocyte capture panel is the first, with additional tissue-specific panels in development.
It has already enabled EvoLiver™ and underpins precision medicine programs with pharmaceutical partners, including a leading global pharmaceutical company in MASH.
